针对性蛋白质降解剂的临床翻译
Nikki R Kong1,2, Lyn H Jones1,2
1Center for Protein Degradation, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Clinical pharmacology and therapeutics
|July 3, 2023
概括
向蛋白降解 (TPD) 提供了一种新的治疗方法. 本综述检查了临床试验中的TPD药物,重点关注分子和PROTAC,以及它们对不可药物点的潜力.
科学领域:
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 向蛋白质降解 (TPD) 是一个有前途的治疗策略.
- 分子粘合剂和蛋白质溶解向仿真体 (PROTACs) 是TPD的关键模式.
- 这些技术降解了以前被认为是不可抗药的蛋白质.
研究的目的:
- 审查目前正在临床试验中的TPD治疗方法.
- 分析从堕落的发展中吸取的教训.
- 从TPD中新出现的人类数据提供见解.
主要方法:
- 对TPD药物的临床试验数据的审查.
- 分子和PROTAC机制的分析.
- 检查E3酶利用率,主要是CRL4CRBN.
主要成果:
- 进入临床试验的TPD药物的显著增加,特别是在癌症方面.
- 大多数TPD药物使用CRL4CRBN E3结合酶.
- 目前,有针对性的感兴趣蛋白 (POI) 的多样性有限.
结论:
- TPD显示出显著的治疗前景,特别是在瘤学中.
- 发展见解和人类数据对于推进TPD至关重要.
- 扩大向蛋白和E3结合酶的范围是未来TPD成功的关键.
相关概念视频
Regulated Protein Degradation
2.6K
2.6K
The Proteasome
8.8K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
8.8K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Prodrugs
2.7K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.7K
Directing Proteins to the Rough Endoplasmic Reticulum
7.3K
The organelle-specific signaling sequences direct proteins synthesized in the cytosol to their final destination like ER, mitochondria, peroxisomes, etc. Some of the proteins directed to ER are then trafficked via vesicles to other organelles within the cell or the extracellular environment through the Golgi complex. For example, the rough ER synthesizes soluble proteins for transportation to the lysosomes or secretion out of the cell. It can also synthesize transmembrane proteins that can...
7.3K
Drug Biotransformation: Overview
2.5K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.5K


